About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2025№3
Additional benefits of menopausal hormone...

Additional benefits of menopausal hormone therapy with drospirenone for healthy longevity

DOI
https://dx.doi.org/10.18565/aig.2025.70

Andreeva E.N., Yureneva S.V., Yarmolinskaya M.I.

1) National Medical Research Centre for Endocrinology, Ministry of Health of Russia, Moscow, Russia; 2) Russian University of Medicine, Ministry of Health of Russia, Moscow, Russia; 3) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 4) D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, St. Petersburg, Russia; 5) I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, St. Petersburg, Russia

The increase in life expectancy means that women will live a significant portion of their lives in postmenopausal period. This period of the woman’s life is characterized by an increase in the number of comorbidities;  many postmenopausal patients have cardiovascular and endocrine diseases, cerebrovascular disorders, etc. Therefore, it is important to identify risk factors and prevent them, diagnose diseases in their early stages in peri- and early postmenopausal women, and treat them appropriately using a multidisciplinary medical approach. Current guidelines suggest that menopausal hormone therapy (MHT) is the most effective treatment for menopausal symptoms. It may have preventive effects for a number of cardiometabolic diseases although this is not among the approved indications, and it may improve women’s long-term quality of life. The use of the combination of estradiol and drospirenone provides additional benefits for health and quality of life in postmenopausal women. These benefits include correction of symptoms associated with estrogen deficiency and a protective effect of drospirenone on the endometrium due to its marked progestogenic effect. It also prevents fluid retention and preserves/improves body composition due to antimineralocorticoid effect. Moreover, it normalizes androgen status by correcting relative hyperandrogenism in early postmenopausal period, which helps prevent the development of metabolic and cardiovascular disorders.
Conclusion: The prescription of MHT with drospirenone in early postmenopausal period and continuous ultralow-dose therapy in late postmenopausal period may be the foundation for preserving women’s long-term health and quality of life, which is fully consistent with the principles of the 5 P’s of modern medicine. Such an approach to the management of postmenopausal women will also contribute to the implementation of the national strategy aimed at preserving active and healthy longevity.

Authors’ contributions: Yarmolinskaya M.I., Andreeva E.N., Yureneva S.V. – developing the concept of the study, making the plan of the article, collection and analysis of the data, drawing conclusions, preparing the manuscript.
Conflicts of interes: The authors declare no possible conflicts of interest.
Funding: The work was supported by Bayer.
For citation: Andreeva E.N., Yureneva S.V., Yarmolinskaya M.I. Additional benefits of 
menopausal hormone therapy with drospirenone for healthy longevity.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (3): 44-55 (in Russian)
https://dx.doi.org/10.18565/aig.2025.70

Keywords

menopausal transition
postmenopausal period
menopausal hormone therapy
17-β estradiol
drospirenone
healthy longevity
Full text (in Russian)

References

  1. Keating N.A. Research framework for the United Nations Decade of Healthy Ageing (2021-2030). Eur. J. Ageing. 2022; 19(3): 775-87. https://dx.doi.org/10.1007/s10433-021-00679-7
  2. ВОЗ. Десятилетие здорового старения (2021-2030 гг.) Доступно по: https://www.who.int/ru/initiatives/decade-of-healthy-ageing [WHO’s work on the UN Decade of Healthy Agening (2021-2030). Available at: https://www.who.int/ru/initiatives/decade-of-healthy-ageing].
  3. Panay N., Ang S.B., Cheshire R., Goldstein S.R., Maki P., Nappi R.E.; International Menopause Society Board. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. Climacteric. 2024; 27(5): 441-57. https://dx.doi.org/10.1080/13697137.2024.2394950.
  4. Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V., Fonarow G.C., Warner J.J., Alger H.M. et al.; American Heart Association. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: A Presidential Advisory from the American Heart Association. Circulation. 2022; 145(23): e1059-e1071. https://dx.doi.org/10.1161/CIR.0000000000001071.
  5. Maas A.H.E.M., Rosano G., Cifkova R., Chieffo A., van Dijken D., Hamoda H. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021; 42(10): 967-84. https://dx.doi.org/10.1093/eurheartj/ehaa1044.
  6. Nappi R.E., Panay N., Davis S.R. In search of a well-balanced narrative of the menopause momentum. Climacteric 2024; 27(3): 223-5. https://dx.doi.org/10.1080/13697137.2024.2339129.
  7. Garmany A., Yamada S., Terzic A. Longevity leap: mind the healthspan gap. NPJ Regen. Med. 2021; 6(1): 57. https://dx.doi.org/10.1038/s41536-021-00169-5.
  8. DeVito L.M., Barzilai N., Cuervo A.M., Niedernhofer L.J., Milman S., Levine M. et al. Extending human healthspan and longevity: a symposium report. Ann. N. Y. Acad. Sci. 2022; 1507(1): 70-83. https://dx.doi.org/10.1111/nyas.14681.
  9. Единый план по достижению национальных целей развития Российской Федерации до 2030 года и на перспективу до 2036 года (утв. Правительством Российской Федерации №309 от 7 мая 2024 г. № 309). Доступно по: http://static.government.ru/media/files/ZsnFICpxWknEXeTfQdmcFHNei2FhcR0A.pdf [A unified plan to achieve the national development goals of the Russian Federation until 2030 and for the future until 2036 (approved by Government of the Russian Federation No. 309 dated May 7, 2024 No. 309. Available at: http://static.government.ru/media/files/ZsnFICpxWknEXeTfQdmcFHNei2FhcR0A.pdf (in Russian)].
  10. Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.267.
  11. Распоряжение Правительства РФ от 29 декабря 2022 г. № 4356-р «Об утверждении Национальной стратегии действий в интересах женщин на 2023-2030 гг.». Доступно по: https://www.garant.ru/products/ipo/prime/doc/405965441/ [Order of the Government of the Russian Federation of December 29, 2022 No. 4356-r "On approval of the National Strategy of Action for Women for 2023-2030." Available at: https://www.garant.ru/products/ipo/prime/doc/405965441/ (in Russian)].
  12. Al Wattar B.H., Rogozińska E., Vale C., Fisher D., Petersen I., Nicum S. et al. Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need. Climacteric. 2024; 27(2): 154-158. https://dx.doi.org/10.1080/13697137.2023.2297880.
  13. Stuenkel C.A. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2024; 27(1): 5-15. https://dx.doi.org/10.1080/13697137.2023.2259793.
  14. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028.
  15. Davis S.R., Taylor S., Hemachandra C., Magraith K., Ebeling P.R., Jane F. et al. The 2023 Practitioner's toolkit for managing menopause. Climacteric. 2023; 26(6): 517-36. https://dx.doi.org/10.1080/13697137.2023.2258783.
  16. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины, 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women. 2024. (in Russian)].
  17. Burki T. Rossella Nappi: taking the stigma out of menopause. Lancet Diabetes Endocrinol. 2023; 11(4): 232. https://dx.doi.org/10.1016/S2213-8587(23)00057-8.
  18. Kravitz H.M., Kazlauskaite R., Joffe H. Sleep, health, and metabolism in midlife women and menopause: food for thought. Obstet. Gynecol. Clin. North Am. 2018; 45(4): 679-94. https://dx.doi.org/10.1016/j.ogc.2018.07.008.
  19. https://www.thelancet.com/series/menopause-2024
  20. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al.; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015; 175(4): 531-9. https://dx.doi.org/10.1001/jamainternmed.2014.8063.
  21. Thurston R.C., Aslanidou Vlachos H.E., Derby C.A., Jackson E.A., Brooks M.M., Matthews K.A. et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J. Am. Heart Assoc. 2021; 10(3): e017416. https://dx.doi.org/10.1161/JAHA.120.017416.
  22. Anagnostis P., Lambrinoudaki I., Stevenson J.C., Goulis G.D. Menopause-associated risk of cardiovascular disease. Endocr. Connect. 2022; 11(4): e210537. https://dx.doi.org/10.1530/EC-21-0537.
  23. Jeong H.G., Park H. Metabolic disorders in menopause. Metabolites. 2022; 12(10): 954. https://dx.doi.org/10.3390/metabo12100954.
  24. Stuenkel C.A. Cardiovascular disease in women: take it to heart. Climacteric. 2024; 27(1): 2-4. https://dx.doi.org/10.1080/13697137.2023.2286140.
  25. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: A Scientific Statement from the American Heart Association. Circulation. 2020; 142(25): e506-e532. https://dx.doi.org/10.1161/CIR.0000000000000912.
  26. Davis S.R., Baber R.J. Treating menopause ─ MHT and beyond. Nat. Rev. Endocrinol. 2022; 18(8): 490-502. https://dx.doi.org/10.1038/s41574-022-00685-4.
  27. Grandi G., Piacenti I., Volpe A., Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol. Endocrinol. 2014; 30(9): 676-80. https://dx.doi.org/10.3109/09513590.2014.922947.
  28. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol. 2004; 217(1-2): 255-61. https://dx.doi.org/10.1016/j.mce.2003.10.030.
  29. Funder J.W. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol. Cell. Endocrinol. 2004; 217(1-2): 263-9. https://dx.doi.org/10.1016/j.mce.2003.10.054.
  30. Tominaga T., Suzuki H., Ogata Y., Matsukawa S., Saruta T. The role of sex hormones and sodium intake in postmenopausal hypertension. J. Hum. Hypertens. 1991; 5(6): 495-500.
  31. Hirschberg A.L. Approach to investigation of hyperandrogenism in a postmenopausal woman. J. Clin. Endocrinol. Metab. 2023; 108(5): 1243-53. https://dx.doi.org/10.1210/clinem/dgac673.
  32. Cappola A.R., Auchus R.J., El-Hajj Fuleihan G., Handelsman D.J., Kalyani R.R., McClung M. et al. Hormones and aging: An Endocrine Society Scientific Statement. J. Clin. Endocrinol. Metab. 2023; 108(8): 1835-74. https://dx.doi.org/10.1210/clinem/dgad225.
  33. Hirschberg A.L. Hyperandrogenism and cardiometabolic risk in pre- and postmenopausal women-What is the evidence? J. Clin. Endocrinol. Metab. 2024; 109(5): 1202-13. https://dx.doi.org/10.1210/clinem/dgad590.
  34. Chistiakov D.A., Myasoedova V.A., Melnichenko A.A., Grechko A.V., Orekhov A.N. Role of androgens in cardiovascular pathology. Vasc. Health Risk Manag. 2018; 14: 283-90. https://dx.doi.org/10.2147/VHRM.S173259.
  35. Stone T., Stachenfeld N.S. Pathophysiological effects of androgens on the female vascular system. Biol. Sex. Differ. 2020; 11(1):45. https://dx.doi.org/10.1186/s13293-020-00323-6.
  36. Alemany M. The roles of androgens in humans: biology, metabolic regulation and health. Int. J. Mol. Sci. 2022; 23(19): 11952. https://dx.doi.org/10.3390/ijms231911952.
  37. Opoku A.A., Abushama M., Konje J.C. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol. 2023; 88: 102348. https://dx.doi.org/10.1016/j.bpobgyn.2023.102348.
  38. Wang J., Wu D., Guo H., Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019; 236: 116940. https://dx.doi.org/10.1016/j.lfs.2019.116940.
  39. Galmés-Pascual B.M., Martínez-Cignoni M.R., Morán-Costoya A., Bauza-Thorbrügge M., Sbert-Roig M., Valle A. et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. Free Radic. Biol. Med. 2020; 150: 148-60. https://dx.doi.org/10.1016/j.freeradbiomed.2020.02.016.
  40. Li J., Papadopoulos V., Vihma V. Steroid biosynthesis in adipose tissue. Steroids. 2015; 103: 89-104. https://dx.doi.org/10.1016/j.steroids.2015.03.016.
  41. Kuryłowicz A. Estrogens in adipose tissue physiology and obesity-related dysfunction. Biomedicines. 2023; 11(3): 690. https://dx.doi.org/10.3390/biomedicines11030690.
  42. El Khoudary S.R., Greendale G., Crawford S.L., Avis N.E., Brooks M.M., Thurston R.C. et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019; 26(10): 1213-27. https://dx.doi.org/10.1097/GME.0000000000001424.
  43. Gold E.B., Crawford S.L., Shelton J.F., Tepper P.G., Crandall C.J., Greendale G.A. et al. Longitudinal analysis of changes in weight and waist circumference in relation to incident vasomotor symptoms: the Study of Women's Health Across the Nation (SWAN). Menopause. 2017; 24(1): 9-26. https://dx.doi.org/10.1097/GME.0000000000000723.
  44. Юренева С.В. Ожирение в период менопаузального перехода: как прервать негативные связи и предупредить последствия? Акушерство и гинекология. 2024; 11: 56-65. [Yureneva S.V. Obesity during the menopausal transition: how to break negative connections and prevent consequences? Obstetrics and Gynecology. 2024; (11): 56-65 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.291
  45. Understanding the link between obesity and cancer. A conversation with Colleen K. Spees, PhD, RD, FAND, FAHA, 2024. Available at: https://ascopost.com/issues/december-10-2024/understanding-the-link-between-obesity-and-cancer/
  46. Manni A., El-Bayoumy K. Lifestyle modifications and breast cancer risk. Cancers (Basel). 2023; 15(11): 2870. https://dx.doi.org/10.3390/cancers15112870.
  47. Hallajzadeh J., Khoramdad M., Izadi N., Karamzad N., Almasi-Hashiani A., Ayubi E. et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018; 25(10): 1155-64. https://dx.doi.org/10.1097/GME.0000000000001136.
  48. Ou Y.J., Lee J.I., Huang S.P., Chen S.C., Geng J.H., Su C.H. Association between menopause, postmenopausal hormone therapy and metabolic syndrome. J. Clin. Med. 2023; 12(13): 4435. https://dx.doi.org/10.3390/jcm12134435.
  49. Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10. https://dx.doi.org/10.1016/j.maturitas.2018.08.009.
  50. Zhu D., Chung H.F., Dobson A.J., Pandeya N., Anderson D.J., Kuh D. et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am. J. Obstet. Gynecol. 2020; 223(6): 898.e1-898.e16. https://dx.doi.org/10.1016/j.ajog.2020.06.039.
  51. Rees M., Abernethy K., Bachmann G., Bretz S., Ceausu I., Durmusoglu F. et al. The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement. Maturitas. 2022; 158: 70-7. https://dx.doi.org/10.1016/j.maturitas.2021.12.001.
  52. Lega I.C., Fine A., Antoniades M.L., Jacobson M. A pragmatic approach to the management of menopause. CMAJ. 2023; 195(19): E677-E682. https://dx.doi.org/10.1503/cmaj.221438.
  53. Brown H.L., Warner J.J., Gianos E., Gulati M., Hill A.J., Hollier L.M. et al.; American Heart Association and the American College of Obstetricians and Gynecologists. Promoting Risk Identification and Reduction of Cardiovascular Disease in Women Through Collaboration With Obstetricians and Gynecologists: A Presidential Advisory From the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation. 2018; 137(24): e843-e852. https://dx.doi.org/10.1161/CIR.0000000000000582.
  54. Capozzi A., Scambia G., Lello S. Clinical pharmacology of progestins. Minerva Obstet. Gynecol. 2022; 74(4): 364-76. https://dx.doi.org/10.23736/S2724-606X.21.04881-8.
  55. Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003; 68(10-13): 891-905. https://dx.doi.org/10.1016/j.steroids.2003.08.008.
  56. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62(1): 29-38. https://dx.doi.org/10.1016/s0010-7824(00)00133-5.
  57. Regidor P., Schindler A.E. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017; 8: 83334-42. https://dx.doi.org/10.18632/oncotarget.19833.
  58. Краснопольский В.И., Зайдиева Я.З. Фармакологические и клинические аспекты менопаузальной гормонотерапии. Информационно-образовательное руководство. М.; 2016. 51 c. [Krasnopolsky V.I., Zaidieva Ya.Z. Pharmacological and clinical aspects of menopausal hormone therapy. Information and educational guidance. Moscow; 2016. 51 p. (in Russian)].
  59. Thurston R.C., Chang Y., Barinas-Mitchell E., Jennings J.R., von Känel R., Landsittel D.P. et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause. 2018; 25(11): 1354-61. https://dx.doi.org/10.1097/GME.0000000000001239.
  60. Muka T., Oliver-Williams C., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One. 2016; 11(6): e0157417. https://dx.doi.org/10.1371/journal.pone.0157417.
  61. Thurston R.C., Johnson B.D., Shufelt C.L., Braunstein G.D., Berga S.L., Stanczyk F.Z. et al. Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause. 2017; 24(2): 126-32. https://dx.doi.org/10.1097/GME.0000000000000731.
  62. Franco O.H., Muka T., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R. et al. Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and meta-analysis. Maturitas. 2015; 81(3): 353-61. https://dx.doi.org/10.1016/j.maturitas.2015.04.016.
  63. Юренева С.В., Ильина Л.М., Эбзиева З.Х. Огонь, мерцающий в сосудах. Репродуктивное старение женщин и эндотелиальная дисфункция. Status Praesens. 2015; 6(29): 45-52. [Yureneva S.V., Il’ina L.M., Ebzieva Z.Kh. Fire Flickering in the Vessels: Female Reproductive Aging and Endothelial Dysfunction. Status Praesens. 2015; 6(29): 45-52. (in Russian)].
  64. Archer D.F. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007; 10(Suppl. 1): 3-10. https://dx.doi.org/10.1080/13697130601114859.
  65. Archer D.F., Schmelter T., Schaefers M., Gerlinger C., Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014; 21(3): 227-35. https://dx.doi.org/10.1097/GME.0b013e31829c1431.
  66. Беркетова Т.Ю., Романцова Т.И., Погорелова А.С., Саркисян А.З., Рагозин А.К. Влияние препарата «Анжелик» на качество сексуальной жизни женщин с СД 2 типа в постменопаузе. Ожирение и метаболизм. 2008; 3: 31-6. [Berketova T.Yu., Romantsova T.I., Pogorelova A.S., Sarkisyan A.Z., Ragozin A.K. The effect of Angeliq on the quality of sexual life of postmenopausal women with type 2 diabetes mellitus. Obesity and Metabolism. 2008; 3: 31-6. (in Russian)].
  67. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., Дзеранова Л.К., Драпкина О.М., Древаль А.В., Дубовицкая Т.А., Дудинская Е.Н., Ершова О.Б., Загородний Н.В., Илюхина О.Б., Канис Д.А., Крюкова И.В., Лесняк О.М., Мамедова Е.О., Марченкова Л.А., Мельниченко Г.А., Никанкина Л.В., Никитинская О.А., Петряйкин А.В., Пигарова Е.А., Родионова С.С., Рожинская Л.Я., Скрипникова И.А., Тарбаева Н.В., Ткачева О.Н., Торопцова Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021; 24(2) :4-47. [Belaya Zh.E., Belova K.Yu., Biryukova E.V., Dedov I.I., Dzeranova L.K., Drapkina O.M., Dreval A.V., Dubovitskaya T.A., Dudinskaya E.N., Ershova O.B., Zagorodniy N.V., Ilyukhina O.B., Kanis J.A., Kryukova I.V., Lesnyak O.M., Mamedova E.O., Marchenkova L.A., Mel’nichenko G.A., Nikankina L.V., Nikitinskaya O.A., Petryaikin A.V., Pigarova E.A., Rodionova S.S., Rozhinskaya L.Ya., Skripnikova I.A., Tarbaeva N.V., Tkacheva O.N., Toroptsova N.V., Farba L.Ya., Tsoriev T.T., Chernova T.O., Yureneva S.V., Yakushevskaya O.V. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021; 24(2): 4-47. (in Russian)]. https://dx.doi.org/10.14341/osteo12930.
  68. Инструкция по медицинскому применению лекарственного препарата «Анжелик» (Angeliq) от 20.03.2024. [Instructions for the medical use of the drug Angeliq dated 03/20/2024. (in Russian)].
  69. Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016; 19(4): 349-56. https://dx.doi.org/10.1080/13697137.2016.1183624.
  70. https://www.vshouz.ru/news/zayavleniya/wcs-18414/
  71. Stuenkel C.A. Menopause, hormone therapy and diabetes. Climacteric. 2017; 20(1):11-21. https://dx.doi.org/10.1080/13697137.2016.1267723.
  72. Saccomani S., Lui-Filho J.F., Juliato C.R., Gabiatti J.R., Pedro A.O., Costa-Paiva L. Does obesity increase the risk of hot flashes among midlife women?: a population-based study. Menopause. 2017; 24(9): 1065-70. https://dx.doi.org/10.1097/GME.0000000000000884.
  73. Tankó L.B., Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J. Intern. Med. 2005; 258(6): 544-53. https://dx.doi.org/10.1111/j.1365-2796.2005.01571.x.
  74. Rizzo M.R., Leo S., De Franciscis P., Colacurci N., Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014; 36(1): 265-74. https://dx.doi.org/10.1007/s11357-013-9554-7.
  75. Miller V.M., Naftolin F., Asthana S., Black D.M., Brinton E.A., Budoff M.J. et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019; 26(9): 1071-84. https://dx.doi.org/10.1097/GME.0000000000001326.
  76. Hodis H.N., Mack W.J., Henderson V.W., Shoupe D., Budoff M.J., Hwang-Levine J. et al.; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 2016; 374(13): 1221-31. https://dx.doi.org/10.1056/NEJMoa1505241.

Received 12.03.2025

Accepted 17.03.2025

About the Authors

Elena N. Andreeva, Dr. Med. Sci., Professor, Deputy Director of the Center – Head of the Institute of Reproductive Medicine, Head of the Department of Endocrine Gynecology, Endocrinology Research Centre, 117292, Russia, Moscow, Dm. Ulyanova str., 11; Professor, Departments of Obstetrics, Gynecology and Reproductive Surgery, Russian University of Medicine, Ministry of Health of Russia, 127006, Russia, Moscow, Dolgorukovskaya str., 4, endogin@mail.ru, SPIN: 1239-2937,
Researcher ID: B-5889-2017, Scopus Author ID: 7102485410, https://orcid.org/0000-0001-8425-0020
Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Science of the Institute of Oncogynecology and Mammology, Professor at the Department of Obstetrics and Gynecology at the Institute of Professional Education, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4, syureneva@gmail.com, SPIN: 3623-9149, Researcher ID: J-5304-2017,
Scopus Author ID: 56299444500, https://orcid.org/0000-0003-2864-066Х
Maria I. Yarmolinskaya, Dr. Med. Sci., Professor of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Head of the Department of Gynecology and Endocrinology, Head of the Center of Diagnostics and Treatment of Endometriosis, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 199034, Russia, St. Petersburg, Mendeleevskaya Line, 3; Professor at the Department of Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, 191015, Russia, St. Petersburg, Kirochnaya str., 41, m.yarmolinskaya@gmail.com, SPIN: 3686-3605, Researcher ID: P-2183-2014,
Scopus Author ID: 7801562649, https://orcid.org/0000-0002-6551-4147
Corresponding author: Maria I. Yarmolinskaya, m.yarmolinskaya@gmail.com

Similar Articles

№4 / 2023
Babaeva N.А., Yureneva S.V., Aleshikova О.I., Yakushevskaya О.V., Ashrafyan L.A.
Impact of hormone therapy on the overall and relapse‑free survival of patients receiving treatment for ovarian cancer
№11 / 2023
Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A.
Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists,Eurasian Association of Therapists, Russian Phlebological Association
№10 / 2022
Akinshina S.V., Koloda Yu.A.
The effect of a new contraceptive with estetrol on the thrombotic safety profile of hormonal contraception
№12 / 2024
Astapovskii A.A., Drozdov V.N., Astapovskaya O.V., Shikh E.V.
Comparative pharmacoeconomic effectiveness of menopausal hormone therapy: oral versus transdermal preparations
№2 / 2023
Tolstov S.N., Salov I.A., Rebrov A.P.
Cardiometabolic risk factors in women undergoing the menopausal transition and the potential of drospirenone-containing contraceptive in the correction of the identified abnormalities
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.